Neurocode Laboratory

Revolutionizing Neurology Testing

Neurocode uses specialized expertise and cutting-edge technologies to provide accurate, repeatable, clinically actionable assays, filling unmet needs in neurodiagnostics.

First-of-its-kind AChR CBA test offered in the U.S.

Offering live cell based assays for antibodies against acetylcholine receptors (AChR CBA)

Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction (NMJ) in which autoantibodies disrupt the communication between nerves and muscle resulting in fatigable weakness of skeletal muscles.1 Autoantibodies to AChR, MuSK, or LRP4 are found in upwards of 90% of adult MG patients and their detection aids physicians in diagnosis of MG2,3.

Cell based assays are a cutting-edge technology that express proteins in live cultured cells. This technique allows us to cluster AChR on the cell surface, which more closely mimics how it is present in vivo at the NMJ and increases sensitivity even to low-affinity AChR antibodies. CBA are extremely sensitive and may detect autoantibodies in some patients that are seronegative by traditional RIPA4,5,6.

How to order a test

Schedule a blood draw

Expertise and excellence in Alzheimer’s disease clinical trials

Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is the most common type of dementia in older adults7. Tracking and diagnosis of AD can be difficult, as the pathological features cannot be directly measured8,9.

Neurocode specializes in state-of-the-art fluid biomarker assays that are revolutionizing AD testing

We have provided our expertise in high-precision ultrasensitive testing to phase 2 and 3 clinical trials. Take advantage of technologies at the forefront of biomarker testing for your secondary endpoint testing or inclusion criteria.

1. Frykman, H., Kumar, P., & Oger, J. (2020). Immunopathology of autoimmune myasthenia gravis: implications for improved testing algorithms and treatment strategies. Front Neurol, 11, 596621. 2. Oger, J., & Frykman, H. (2015). An update on laboratory diagnosis in myasthenia gravis. Clinica Chimica Acta, 449, 43-48. 3. Binks, S., Vincent, A., & Palace, J. (2016). Myasthenia gravis: a clinical-immunological update. J Neurol, 263(4), 826-834. 4. Vincent, A. et al. (2018). Serological and experimental studies in different forms of myasthenia gravis. Ann NY Acad Sci, 1413(1), 143-153. 5. Mirian, A et al. (2022). Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis. J Neurol Sci, 432, 120084. 6. Hoff mann, S. et al. (2023). Autoantibody detection by a live cell-based assay in conventionally antibody-tested triple seronegative Myasthenia gravis. Neuromuscular Disorders. 7. Alzheimer’s Association. 2022 Alzheimer’s disease facts and figures. Alzheimers Dement 2022;18:700–89. PMID:35289055 8. Cohen, Ann D., et al. (2019) Fluid and PET biomarkers for amyloid pathology in Alzheimer’s disease. Molecular and cellular neuroscience 97: 3-17. 9. Wang, Xu, et al. (2018) Competitive immunoassays for the detection of small molecules using single molecule arrays. Journal of the American Chemical Society 140.51: 18132-18139.

To discuss your clinical trial biomarker needs:

Neurocode offers novel assays with clinical impact.